To whom it may concern,

This letter is written in reference to [patient name]. (S)he is a [age]-year-old [race] [male/female] diagnosed with Erdheim-Chester Disease. Erdheim-Chester Disease is a non-Langerhans form of systemic histiocytosis. This progressive disease affects multiple organs and is fatal in 40% of patients in less than three years. Currently, there are not approved treatments for Erdheim-Chester disease. Historic treatments that have been used include corticosteroids, external beam radiation, antiproliferative agents, and interferon. Unfortunately, all of the aforementioned therapies have yielded variable and mostly disappointing results. The purine analog cladiribine has been used in the treatment of multisystem LCH and both newly diagnosed and refractory ECD. Aggressive therapy is warranted in [patient name] as she has [pulmonary, cardiac, neurological] involvement, which portend the worst prognosis. [Patient name] has [provide brief summary of therapies tried and their result, focusing on why cladiribine is the correct therapy.] I therefore request that you authorize use of cladribine.

If you have any questions, comments, or concerns, please feel free to contact me.

Best regards,